cll14: venetoclax-obinutuzumab improves pfs and mrd in untreated, reduced fitness cll
Published 5 years ago • 279 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
5:54
cll14: venetoclax plus obinutuzumab for cll
-
1:24
venetoclax plus obinutuzumab in ckt cll: analysis from the cll14 trial
-
0:45
obinutuzumab and venetoclax for high-risk cll: upcoming cll14 trial
-
0:59
5-year follow-up results of cll14: obinutuzumab venetoclax vs obinutuzumab chlorambucil in cll
-
10:24
fixed-duration therapy with venetoclax-obinutuzumab in frontline cll
-
1:12
frontline, fixed-duration venetoclax/obinutuzumab: pfs and mrd data from cll14
-
4:30
cll14 trial: obinutuzumab venetoclax vs obinutuzumab chlorambucil
-
47:45
simolanvuori mtb kokonaisuudessaan, suonenjoki (vaativa osuus siirtymä simolanvuorelle)
-
5:00
venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline cll: updates from gaia/cll13
-
8:57
venetoclax combined with obinutuzumab for untreated cll (chronic lymphocytic leukemia)
-
5:59
6-year results of cll14: venetoclax-obinutuzumab for previously untreated cll
-
1:14
cll14 trial thoughts
-
3:07
cll14 trial analysis
-
2:03
venetoclax and obinutuzumab combination therapy for cll
-
3:22
combining venetoclax and obinutuzumab in the treatment of cll
-
1:32
cll14: feasibility of fixed-duration frontline therapy in cll
-
0:48
venetoclax and obinutuzumab for cll
-
1:35
cll: venetoclax in combination with obinutuzumab
-
2:56
undetectable mrd after obinutuzumab plus venetoclax in cll
-
1:59
acalabrutinib, venetoclax and obinutuzumab upfront for cll
-
1:02
dr. gerson on venetoclax/obinutuzumab combination in cll